Alvotech is eyeing a European marketing authorization for its AVT06 proposed biosimilar to Eylea (aflibercept) 2mg in the third quarter of next year after the Icelandic firm’s application was accepted for filing by the European Medicines Agency.
Advanz Pharma will serve as Alvotech’s chief commercialization partner in Europe upon potential approval, under the terms of a partnership...






